Inspira Technologies (IINN) shifts medical business to new unit

Rhea-AI Filing Summary

Inspira Technologies Oxy B.H.N. Ltd. has established a wholly owned subsidiary as part of a revised corporate structure. The company plans to transfer its existing medical business activities into this new entity, concentrating its operating business under the subsidiary.

The report is also incorporated by reference into Inspira Technologies’ existing Form F-3 and Form S-8 registration statements, so that these U.S. securities filings reflect the updated corporate structure from the date of this report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2026

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

On March 26, 2026, Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) announced the establishment of a wholly owned subsidiary as part of its corporate structure. The Company intends to transfer its existing medical business activities into the newly formed subsidiary.

This report is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308 and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565, 333-290162 and 333-292592), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inspira Technologies Oxy B.H.N. Ltd.
Date: March 26, 2026	By:	/s/ Dagi Ben-Noon
		Name:	Dagi Ben-Noon
		Title:	Chief Executive Officer

2

FAQ

What corporate change did Inspira Technologies (IINN) disclose in this 6-K?

Inspira Technologies disclosed that it established a wholly owned subsidiary. The company intends to transfer its existing medical business activities into this new entity, updating its corporate structure while keeping ownership at the parent-company level.

How will Inspira Technologies’ medical business be affected by the new subsidiary?

The company plans to move its existing medical business activities into the newly formed wholly owned subsidiary. Operationally, this concentrates its medical business under one legal entity while maintaining full ownership through the parent company.

Is the new Inspira Technologies subsidiary wholly owned by the parent?

Yes, the filing states that the newly established subsidiary is wholly owned. This means Inspira Technologies retains 100% ownership and control over the entity that will hold its transferred medical business activities.

How does this 6-K interact with Inspira Technologies’ F-3 and S-8 filings?

The report is incorporated by reference into Inspira Technologies’ existing Form F-3 and Form S-8 registration statements. This makes the updated corporate structure part of those securities filings from the date this report is submitted.

Does Inspira Technologies’ 6-K mention any change to its medical activities?

The filing notes that existing medical business activities are intended to be transferred into the new subsidiary. It does not describe changes in the nature of those activities, only their placement within the corporate structure.